3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Colorectal Neoplasms
6
Carcinoma, Hepatocellular
6
Sarcoma
2
Rectal Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Gastrointestinal Stromal Tumors
2
Solid Malignant Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Piebaldism
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Liver Metastasis Colon Cancer
1
HER2 IHC3+ Advanced Colorectal Cancer
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Disease Progression
1
Cholangiocarcinoma
1
Bone Neoplasms
1
Interventions
ruxolitinib
13
Cyclophosphamide
5
Tacrolimus
4
Stem Cell Transplantation
4
Specimen Handling
4
fludarabine phosphate
3
Whole-Body Irradiation
3
Peripheral Blood Stem Cell Transplantation
3
Mycophenolic Acid
3
Cyclosporine
3
fludarabine
2
fedratinib
2
Sirolimus
2
Injections
2
Busulfan
2
Blood Component Removal
2
Biopsy
2
Azacitidine
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
veliparib
1
umbralisib
1
thymoglobulin
1
selinexor
1
reparixin
1
piperine
1
pevonedistat
1
pegylated granulocyte colony-stimulating factor
1
navitoclax
1
luspatercept
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Primary Myelofibrosis
×
regorafenib
×
90 days
×
Clear all
No trials found.